Breaking News Instant updates and real-time market news.

LGND

Ligand

$97.32

-1.22 (-1.24%)

18:19
10/07/16
10/07
18:19
10/07/16
18:19

Ligand partner Lundbeck announces FDA approval of Carnexiv injection

Ligand Pharmaceuticals partner Lundbeck announced today that the U.S. FDA has approved Carnexiv injection as a short-term replacement therapy for oral carbamazepine formulations in adults with certain seizure types when oral administration is temporarily not feasible. Carnexiv received orphan drug designation for this indication and will be the first available intravenous formulation of the antiepileptic drug carbamazepine. Lundbeck plans to make Carnexiv commercially available in the United States in early 2017. With the approval, Ligand has earned a $1.25M milestone payment. Ligand is also entitled to receive a royalty of 2.75% on net sales of Carnexiv.

LGND Ligand
$97.32

-1.22 (-1.24%)

09/07/16
ROTH
09/07/16
NO CHANGE
Target $149
ROTH
Buy
Ligand has 'major catalyst' ahead, says Roth Capital
Roth Capital analyst Joseph Pantginis says Ligand (LGND) is expecting a "major catalyst" this month namely the Phase IIb sparsentan data in focal segmental glomerulosclerosis patients being developed by partner Retrophin (RTRX). In a separate note to investors, Pantginis also said that the Breakthrough Therapy Designation of SAGE Therapeutics' (SAGE) '547 for postpartum depression may expedite its development and approval for use in the clinic, noting that the company has an agreement of 3% royalty payment to Ligand for potential sales of the drug. The analyst recommends steady accumulation of Ligand's stock as he anticipates that current revenue streams from partnered products and the broad "in development" portfolio are poised to drive significant growth in the near and longer term. He reiterates a Buy rating and $149 price target on Ligand's shares.
09/07/16
ROTH
09/07/16
NO CHANGE
Target $151
ROTH
Buy
Ligand target raised to $151 after sparsentan data at Roth Capital
Roth Capital analyst Joseph Pantginis raised his price target for Ligand Pharmaceuticals (LGND) to $151 from $149 after the company's partner Retrophin (RTRX) announced positive data from the sparsentan Phase II study in focal segmental glomerulosclerosis patients. The analyst believes the data support a potential accelerated path forward and he reminds investors that FSGS has no approved therapies. Pantginis calls the data an important win for Ligand and Retrophin. He keeps a Buy rating on Ligand. The stock is up 7% to $115.21 in early trading.
09/07/16
09/07/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. ConocoPhillips (COP) upgraded to Hold from Underperform at Jefferies with analyst Jason Gammel citing valuation and improving financial metrics. 2. DineEquity (DIN) upgraded to Overweight from Sector Weight at KeyBanc with analyst Chris O'Cull saying the stock has reached a good entry point, while its risk/reward ratio is "compelling." 3. Gaming and Leisure Properties (GLPI) upgraded to Overweight at Morgan Stanley. 4. Aviva (AV) upgraded to Buy from Neutral at UBS with the firm saying the company is positioned to be the risk-adjusted dividend leader in the sector. 5. Ligand (LGND) upgraded to Hold from Sell at Deutsche Bank. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/05/16
HCWC
10/05/16
NO CHANGE
Target $160
HCWC
Buy
Ligand price target raised to $160 from $146 at H.C. Wainwright
H.C. Wainwright analyst Carol Ann Werther raised her price target for Ligand Pharmaceuticals to $160 citing three recent positive events, namely positive Phase II focal segmental glomerulosclerosis data from partner Retrophin, the beginning of a Phase II clinical trial with LGD-6972 for the treatment of type 2 diabetes and the licensing of several therapeutic programs to Seelos. Werther keeps a Buy rating on Ligand.

TODAY'S FREE FLY STORIES

$COMP

Nasdaq Composite

08:16
04/28/17
04/28
08:16
04/28/17
08:16
Technical Analysis
Nasdaq Composite: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDX

Nasdaq 100 Index

$5,571.28

30.19686 (0.54%)

08:16
04/28/17
04/28
08:16
04/28/17
08:16
Technical Analysis
Nasdaq 100 Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PH

Parker-Hannifin

$161.98

-2.56 (-1.56%)

08:15
04/28/17
04/28
08:15
04/28/17
08:15
Recommendations
Parker-Hannifin analyst commentary  »

Parker-Hannifin price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:15
04/28/17
04/28
08:15
04/28/17
08:15
General news
U.S. Q1 GDP preview: »

U.S. Q1 GDP preview:…

08:15
04/28/17
04/28
08:15
04/28/17
08:15
General news
Real GDP to be reported at 08:30 »

Real GDP will be reported…

08:15
04/28/17
04/28
08:15
04/28/17
08:15
General news
Employment Cost Index ECI to be reported at 08:30 »

Employment Cost Index ECI…

08:15
04/28/17
04/28
08:15
04/28/17
08:15
General news
GDP price index to be reported at 08:30 »

GDP price index will be…

DB

Deutsche Bank

$18.15

-0.69 (-3.66%)

, C

Citi

$59.39

-0.55 (-0.92%)

08:14
04/28/17
04/28
08:14
04/28/17
08:14
Hot Stocks
Deutsche Bank confirms James von Moltke to succeed Marcus Schenck as CFO »

Deutsche Bank's (DB)…

DB

Deutsche Bank

$18.15

-0.69 (-3.66%)

C

Citi

$59.39

-0.55 (-0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 25

    Jul

WDC

Western Digital

$85.71

1.1 (1.30%)

08:14
04/28/17
04/28
08:14
04/28/17
08:14
Downgrade
Western Digital rating change  »

Western Digital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$918.38

9.09 (1.00%)

08:13
04/28/17
04/28
08:13
04/28/17
08:13
Recommendations
Amazon.com analyst commentary  »

Amazon.com price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

  • 16

    May

  • 23

    May

LH

LabCorp

$139.68

0.99 (0.71%)

08:13
04/28/17
04/28
08:13
04/28/17
08:13
Hot Stocks
LabCorp to exclusively offer M3 Checklist for mental illness »

LabCorp and M-3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    May

ATTO

Atento

$8.85

-0.1 (-1.12%)

08:13
04/28/17
04/28
08:13
04/28/17
08:13
Earnings
Atento announces prepayment of $27M Brazilian debentures »

Atento made a $26.7M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 11

    May

08:12
04/28/17
04/28
08:12
04/28/17
08:12
Conference/Events
Cowen analysts hold an analyst/industry conference call »

Analysts provide an…

TER

Teradyne

$36.35

2.58 (7.64%)

08:12
04/28/17
04/28
08:12
04/28/17
08:12
Recommendations
Teradyne analyst commentary  »

Teradyne price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

  • 04

    May

  • 21

    Jun

EXPE

Expedia

$136.20

0.45 (0.33%)

08:12
04/28/17
04/28
08:12
04/28/17
08:12
Recommendations
Expedia analyst commentary  »

Expedia price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 16

    May

LLL

L3 Technologies

$173.94

2.18 (1.27%)

08:12
04/28/17
04/28
08:12
04/28/17
08:12
Recommendations
L3 Technologies analyst commentary  »

L3 Technologies price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBH

Zimmer Biomet

$118.10

-7.22 (-5.76%)

, SYK

Stryker

$135.37

-0.82 (-0.60%)

08:11
04/28/17
04/28
08:11
04/28/17
08:11
Downgrade
Zimmer Biomet, Stryker rating change  »

Zimmer Biomet downgraded…

ZBH

Zimmer Biomet

$118.10

-7.22 (-5.76%)

SYK

Stryker

$135.37

-0.82 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 03

    May

  • 04

    May

PTEN

Patterson-UTI

$21.93

-1.07 (-4.65%)

08:11
04/28/17
04/28
08:11
04/28/17
08:11
Recommendations
Patterson-UTI analyst commentary  »

Patterson-UTI weakness a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

MGA

Magna

$41.40

0.56 (1.37%)

08:11
04/28/17
04/28
08:11
04/28/17
08:11
Hot Stocks
Magna enters joint venture with Chinese seating supplier »

Magna has entered into a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    May

  • 11

    May

XOM

Exxon Mobil

$81.26

-0.14 (-0.17%)

08:11
04/28/17
04/28
08:11
04/28/17
08:11
Hot Stocks
Exxon Mobil says Q1 Chemical earnings impacted primarily by lower margins »

Exxon Mobil reports Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

RWLK

ReWalk Robotics

$1.45

-0.2 (-12.12%)

08:10
04/28/17
04/28
08:10
04/28/17
08:10
Hot Stocks
ReWalk Robotics names Jodi Gricci as Chief Commercial Officer »

ReWalk Robotics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

HON

Honeywell

$129.88

-0.22 (-0.17%)

08:10
04/28/17
04/28
08:10
04/28/17
08:10
Periodicals
Honeywell talks with Third Point still friendly, CNBC's Faber says »

Talks between Honeywell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

FSS

Federal Signal

$15.38

0.98 (6.81%)

08:10
04/28/17
04/28
08:10
04/28/17
08:10
Hot Stocks
Federal Signal awarded $128K of legal costs in hearing loss litigation »

Federal Signal announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$0.10

-0.0099 (-9.00%)

08:09
04/28/17
04/28
08:09
04/28/17
08:09
Hot Stocks
CEL-SCI says European Patent office to grant new Multikine patent »

CEL-SCI Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYF

Synchrony

$33.05

-0.18 (-0.54%)

08:09
04/28/17
04/28
08:09
04/28/17
08:09
Technical Analysis
Synchrony drops sharply after earnings miss consensus »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 18

    May

  • 31

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.